Nicotine Lozenges Market Scope
Nicotine gum and lozenges are each popular and convenient forms of nicotine replacement medical care. These are smoking cessation products that facilitate smokers’ bit by bit overcome drug addiction. Nicotine is free by chewing the gum or lozenge and it's absorbed into the blood through the liner of the mouth, that bit by bit reduces smokers’ want for nicotine. Nicotine Lozenges are hard candy-like pill that contains a dose of nicotine polacrilex and dissolves slowly within the mouth to release the nicotine over the course of twenty to half-hour. It helps individuals in quitting the habit of smoking. to beat drug addiction these smoking stop products facilitate smokers. These products facilitate in relieving the symptoms that occur once a smoker tries to quit smoking. Nicotine Lozenges are absorbed through the liner of the mouth and enter into the blood vessels that are usually accessible over the counter usually found in two mg, four mg strengths, and alternative strengths are accessible. Nicotine lozenges are accessible in numerous flavors, brands and a number of other varieties and dosages are accessible according to nicotine dependence. It's prescribed and prompt by the doctors to not use over lozenges in 6 hours or twenty lozenges per day. It's counseled that nicotine lozenges are to be unbroken within the original container, at room temperature removed from excessive heat or wet.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
Key Companies Profiled | Cipla Ltd. (India), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson (United States), Novartis International AG (Switzerland), Pfizer, Inc. (United States), Perrigo Company plc (Ireland), ITC Limited (India), Dr. Reddy's Laboratories (India) and Takeda Pharmaceutical Co., Ltd. (Japan) |
CAGR | % |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Vendors will contribute to the maximum growth of Global Nicotine Lozenges market throughout the predicted period.
Cipla Ltd. (India), GlaxoSmithKline plc (United Kingdom), Johnson & Johnson (United States), Novartis International AG (Switzerland), Pfizer, Inc. (United States), Perrigo Company plc (Ireland), ITC Limited (India), Dr. Reddy's Laboratories (India) and Takeda Pharmaceutical Co., Ltd. (Japan) are some of the key players that are part of study coverage.
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.
Segmentation Overview
The study have segmented the market of Global Nicotine Lozenges market by Type , by Application (Male and Female) and Region with country level break-up.
On the basis of geography, the market of Nicotine Lozenges has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
region held largest market share in the year 2023.
On 14th July 2020, Dr.Reddy’s had launched over-the-counter Nicotine Polacriles Lozenges in the United States market. These lozenges will be used for the cessation of smoking. The launch is under the brand version of Nicorette Lozenges in the US market.
Influencing Trend:
Rising Trend in The Increasing Awareness About the Ill Effects and Increase in School-Based Educational Campaigns
Market Growth Drivers:
Increase in The Cases of Lung Cancer, Increasing Smoking Cigarettes and Increasing Cases Regarding Cardiac Issues
Challenges:
Lack of Awareness of the Cessation Aid
Restraints:
Fluctuating Price of Raw Materials and High Cost of The Product
Opportunities:
Initiatives by Government to Impose High Tax on Public and Government to Ban Cigarette Products in Public Places
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Nicotine Lozenges, Suppliers and Distributors of Nicotine Lozenges, Venture Capitalists and Private Equity Firms and End-Use Industry